Physician profile
John Hodges
NPI 1063805737
$3,304.23
in general payments reported to CMS, 2019-2025
33 companies · $99.26 in 2025
The $99.26 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,209 · 2022: $867 · 2023: $116 · 2024: $13.24 · 2025: $99.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $749.64 | 2021-2023 | |
| Amgen INC. | $242.45 | 2021-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $238.18 | 2021 | |
| Lilly USA, LLC | $235.94 | 2021-2023 | Mounjaro |
| Daiichi Sankyo INC. | $168.42 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.84 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $146.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.82 | 2021-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $129.89 | 2022 | |
| Novo Nordisk INC | $125.27 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $112.34 | 2021-2022 | |
| Astellas Pharma US INC | $106.56 | 2021-2022 | |
| Corcept Therapeutics | $99.26 | 2025 | Korlym |
| Abbott Laboratories | $83.46 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71.75 | 2021 | |
| Nabriva Therapeutics, Plc | $49.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $42.60 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $31.94 | 2021 | |
| Allergan, INC. | $29.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.30 | 2021 | |
| Lundbeck LLC | $20.30 | 2022 | |
| Pharmacosmos Therapeutics INC. | $19.50 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.78 | 2021 | |
| Kaleo, INC. | $14.29 | 2021 | |
| Currax Pharmaceuticals LLC | $13.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.98 | 2021 | |
| Antares Pharma, INC. | $12.53 | 2022 | |
| Alkermes, INC. | $12.35 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.71 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.51 | 2021 | |
| Genentech USA, INC. | $11.21 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.